Cell-based gene therapy experiments in murine experimental autoimmune encephalomyelitis (Q40445781)

20 September 2017

title

Cell-based gene therapy experiments in murine experimental autoimmune encephalomyelitis (English)

1 reference

20 September 2017

0 references

Louie KA

1 reference

20 September 2017

Weiner LP

1 reference

20 September 2017

Du J

1 reference

20 September 2017

Kochounian HH

1 reference

20 September 2017

Fling SP

1 reference

20 September 2017

Wei W

1 reference

20 September 2017

McMillan M

1 reference

20 September 2017

publication date

1 July 2005

1 reference

20 September 2017

1 reference

20 September 2017

1 reference

20 September 2017

1 reference

20 September 2017

page(s)

1145-1153

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302503

20 September 2017

1 reference

Gene therapy of human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302503

The current status of clinical gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302503

Human gene therapy comes of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302503

New concepts in the immunopathogenesis of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302503

Immunological aspects of demyelinating diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302503

Multiple sclerosis: a pivotal role for the T cell in lesion development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302503

A gender gap in autoimmunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302503

HLA-DR2 dose effect on susceptibility to multiple sclerosis and influence on disease course

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302503

HLA typing in the United Kingdom multiple sclerosis genome screen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302503

HL-A antigens and multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302503

Gene therapy in autoimmune, demyelinating disease of the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302503

The therapeutic use of gene therapy in inflammatory demyelinating diseases of the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302503

Gene therapy in experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302503

The application of gene therapy in autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302503

Treatment of autoimmune disease by adoptive cellular gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302503

T cell response in experimental autoimmune encephalomyelitis (EAE): role of self and cross-reactive antigens in shaping, tuning, and regulating the autopathogenic T cell repertoire

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302503

Increased frequency of interleukin 2-responsive T cells specific for myelin basic protein and proteolipid protein in peripheral blood and cerebrospinal fluid of patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302503

Minireview: autoimmune responses to myelin proteolipid protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302503

Myelin proteolipid protein: minimum sequence requirements for active induction of autoimmune encephalomyelitis in SWR/J and SJL/J mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302503

Functional evidence for epitope spreading in the relapsing pathology of experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302503

Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302503

Epitope spreading in immune-mediated diseases: implications for immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302503

Gene therapy in a murine model for clinical application to multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302503

Characterization of a major encephalitogenic T cell epitope in SJL/J mice with synthetic oligopeptides of myelin basic protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302503

Reactivity pattern and cytokine profile of T cells primed by myelin peptides in multiple sclerosis and healthy individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302503

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302503

Rat KC cDNA cloning and mRNA expression in lung macrophages and fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302503

Long-term erythropoietin gene expression from transduced cells in bioisolator devices

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302503

Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302503

Immunotherapy of multiple sclerosis: where are we? Where should we go?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302503

Immunotherapy of multiple sclerosis: the end of the beginning

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302503

Antigen-induced regulatory T cells in autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302503

Gene therapy in allergic encephalomyelitis using myelin basic protein-specific T cells engineered to express latent transforming growth factor-beta1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302503

Adoptive immunotherapy of experimental autoimmune encephalomyelitis via T cell delivery of the IL-12 p40 subunit

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302503

Treatment of experimental autoimmune encephalomyelitis with genetically modified memory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302503

Local delivery of interleukin 4 by retrovirus-transduced T lymphocytes ameliorates experimental autoimmune encephalomyelitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302503

Pre-emptive targeting of the epitope spreading cascade with genetically modified regulatory T cells during autoimmune demyelinating disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302503

Complete protection from relapsing experimental autoimmune encephalomyelitis induced by syngeneic B cells expressing the autoantigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302503

Gene transfer of Ig-fusion proteins into B cells prevents and treats autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302503

An unexpected version of horror autotoxicus: anaphylactic shock to a self-peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302503

High frequency of autoreactive myelin proteolipid protein-specific T cells in the periphery of naive mice: mechanisms of selection of the self-reactive repertoire

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302503

Assessment of animal models for MS and demyelinating disease in the design of rational therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302503

Antigen-based immunotherapy for autoimmune disease: from animal models to humans?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302503

Antigen-specific immunomodulation via altered peptide ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302503

Specific immunotherapy: one size does not fit all.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302503

Of mice and not men: differences between mouse and human immunology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302503

Frequency of T cells specific for myelin basic protein and myelin proteolipid protein in blood and cerebrospinal fluid in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302503

Isolation and characterization of autoreactive proteolipid protein-peptide specific T-cell clones from multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302503

T cell recognition of myelin proteolipid protein and myelin proteolipid protein peptides in the peripheral blood of multiple sclerosis and control subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302503

Compilation and analysis of sequences upstream from the translational start site in eukaryotic mRNAs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302503

CD8+ T cells recognize an inclusion membrane-associated protein from the vacuolar pathogen Chlamydia trachomatis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302503

Induction of a non-encephalitogenic type 2 T helper-cell autoimmune responsein multiple sclerosis after administration of an altered peptide ligand ina placebo-controlled, randomized phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302503

T-cell recognition of an immuno-dominant myelin basic protein epitope in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302503

Genetic basis for clinical expression in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302503

7 January 2021

Pathologic role and temporal appearance of newly emerging autoepitopes in relapsing experimental autoimmune encephalomyelitis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302503

7 January 2021

The epitope spreading cascade during progression of experimental autoimmune encephalomyelitis and multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302503

7 January 2021

Quantification of self-recognition in multiple sclerosis by single-cell analysis of cytokine production

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302503

7 January 2021

Survival of macroencapsulated allogeneic parathyroid tissue one year after transplantation in nonimmunosuppressed humans.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302503

7 January 2021

The ups and downs of multiple sclerosis therapeutics

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302503

7 January 2021

Combination of gene delivery and DNA vaccination to protect from and reverse Th1 autoimmune disease via deviation to the Th2 pathway

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302503

7 January 2021

Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302503

7 January 2021

Identifiers

DOI

10.1038/SJ.GT.3302503

1 reference

Dimensions Publication ID

20 September 2017

1011588987

0 references

1 reference